drugset / Trial / NCT00100477
Use of Topotecan in Patients With Refractory Acute Leukemia
Phase 2
Completed
10 enrolled
US Department of Veterans Affairs
Amgen · collabImmunex Corporation · collabSmithKline Beecham · collab
Summary
The purpose of this study is to identify the highest tolerated doses in drugs used to treat aggressive leukemia, lymphoma or multiple myeloma not responding to standard chemotherapy treatment. The drugs being used in this study include drugs frequently used in treating such diseases (mitoxantrone and etoposide) as well as a newer drug that has also been shown to be effective (topotecan).
Timeline
- Start
- 1998-08
- Primary completion
- 2001-01
- Completion
- 2001-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Etoposide | Small molecule | — | — |
| Subject | Mitoxantrone | Small molecule | — | — |
| Subject | Topotecan | Small molecule | — | — |